Emcure Pharmaceuticals FY26 Revenue Grows 16.6% to ₹92,035 Crore; PAT Up 33.1%
Emcure Pharmaceuticals reported FY26 revenue of ₹92,035 Crore, up 16.6% YoY. PAT increased 33.1% to ₹9,413 Crore. International business grew 22.2% to ₹51,766 Crore. Q1 FY27 revenue rose 22.8% to ₹25,804 Crore, with PAT up 36.2% to ₹2,925 Crore.
The announcement includes comprehensive financial results for the fiscal year and the first quarter, detailing significant revenue and profit growth across domestic and international segments, which is material information for investors.
The company reported strong year-on-year growth in revenue and profit, along with improved margins, indicating a positive financial performance.
Emcure Pharmaceuticals Limited has announced its financial results for the fiscal year ended March 31, 2026 (FY26), reporting a consolidated revenue from operations of ₹92,035 Crore, a growth of 16.6% compared to the previous year. The company's Profit After Tax (PAT) saw a significant increase of 33.1% to ₹9,413 Crore.
The domestic business contributed ₹40,270 Crore to the revenue, marking a 10.0% year-on-year growth, driven by a strengthening chronic-led franchise and increasing market share in key therapy areas like Women's Health and Cardio-metabolics. The international business demonstrated robust growth of 22.2%, reaching ₹51,766 Crore, with Europe, Canada, and Rest of World (RoW) segments all showing strong performance. Europe grew by 25.5% to ₹18,498 Crore, Canada by 18.7% to ₹14,869 Crore, and RoW by 21.8% to ₹18,399 Crore.
EBITDA for FY26 rose by 21.8% to ₹17,886 Crore, with an improved EBITDA margin of 19.4%. The company highlighted its strategic priorities for FY26-FY30, focusing on deepening the domestic franchise, scaling differentiated international portfolios, and translating R&D platforms into commercial launches. Emcure also reported a 4.2% R&D investment as a percentage of FY26 revenue, with a strong pipeline of complex injectables, biologics, and novel drug delivery systems.
For the first quarter of FY27 (Q1 FY27), Emcure reported revenue of ₹25,804 Crore, an increase of 22.8% year-on-year. PAT for the quarter grew by 36.2% to ₹2,925 Crore, with PAT margin improving to 11.3%. The company's balance sheet shows total equity and liabilities of ₹96,125 Crore as of March 31, 2026.
What to do with a filing like this
Emcure Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Emcure Pharmaceuticals Limited. Read the original for the full detail.